^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Pancreatic Cancer
    Drug:gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ASCO.org
    Title:

    Metastatic Pancreatic Cancer: ASCO Guideline Update

    Published date:
    08/05/2020
    Excerpt:
    Recommendations…First-Line Treatment…Gemcitabine plus nab-paclitaxel is recommended…Recommendations…First-Line Treatment…Gemcitabine alone is recommended…The addition of nabpaclitaxel or capecitabine or erlotinib to gemcitabine may be offered in this setting…
    DOI:
    10.1200/JCO.20.01364 Journal of Clinical Oncology
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    J Clin Oncol
    Title:

    Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC): Outcomes by geographic region

    Published date:
    05/25/2020
    Excerpt:
    Treatment-naive patients with histologically confirmed PC...received nab-P 125 mg/m2 + Gem 1000 mg/m2 or Gem 1000 mg/m2 on days 1, 8, and 15 of six 28-day cycles....The updated OS analysis...revealed a median OS of 41.8 months with nab-P + Gem compared with 37.7 months with Gem alone…
    DOI:
    10.1200/JCO.2020.38.15_suppl.4515
    Trial ID:
    apact